Sep 10, 2018 by Brian Orelli, PhDHere's Why Endocyte Jumped Higher Today and Is Down After HoursA quicker pathway to approval had shares up, then the company decided to use the opportunity to raise additional capital.
Sep 10, 2018 by Brian Orelli, PhDHere's Why Novavax, Inc. Jumped 22.8% in AugustClinical trial progress has investors excited about the vaccine company's future.
Sep 7, 2018 by Brian Orelli, PhDHere's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% TodayInvestors ponder the biotech's secondary offering.
Sep 6, 2018 by Brian Orelli, PhDHere's Why Nektar Therapeutics Jumped 26.4% in AugustInvestors are regaining their confidence in the high-flying oncology company.
Sep 6, 2018 by Brian Orelli, PhDHere's Why Zai Lab Limited Dropped TodayA secondary offering has investors hitting the sell button.
Sep 5, 2018 by Brian Orelli, PhDHere's Why INSYS Therapeutics, Inc. Jumped a Whopping 40.3% in AugustA settlement with the U.S. Department of Justice started August off on a good foot, but the month was capped off with a short squeeze.
Sep 5, 2018 by Brian Orelli, PhDHere's Why Endo International plc Jumped 37.9% Higher in AugustA strong second quarter sends shares higher.
Sep 5, 2018 by Brian Orelli, PhDHere's Why AVEO Pharmaceuticals Inc. Jumped 40% Higher in AugustInvestors jump in ahead of expected clinical trial data.
Aug 31, 2018 by Brian Orelli, PhDHere's Why INSYS Therapeutics Inc. Is on a Rollercoaster: Up 34% Yesterday, Down 12% TodayThe FDA's Fast Track designation isn't all it's cracked up to be.
Aug 30, 2018 by Brian Orelli, PhDWhy K2M Group Holdings, Inc. Acquired a Higher Price TodayStryker is buying the medical device maker. Here's what investors need to know.
Aug 28, 2018 by Brian Orelli, PhDHere's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted TodayThe FDA gives a thumbs down to their triglyceride-lowering drug Waylivra.
Aug 27, 2018 by Brian Orelli, PhDHere's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped TodayA competitor's data wasn't as good as investors feared.
Aug 22, 2018 by Brian Orelli, PhDShould Alnylam's and Ionis' Investors Be Worried About This Recent IPO?There's a new public company with an ATTR drug in mid-stage development.
Aug 20, 2018 by Brian Orelli, PhD3 Things Alnylam's Management Wants Investors to Know About the Launch of OnpattroThe company gives its thoughts on the drug's label, market size, and price.
Aug 16, 2018 by Brian Orelli, PhDShould Gilead Be Worried About This New Monthly HIV Medication?The devil is in the undisclosed details.
Aug 15, 2018 by Brian Orelli, PhDHere's Why Tilray, Inc. and Cronos Group Inc. Jumped Higher TodaySometimes you need a little help from some friends.
Aug 14, 2018 by Brian Orelli, PhDNovo Nordisk's Pricing Pressures Aren't Going AwayPayers continue to seek lower drug prices from the diabetes expert.
Aug 13, 2018 by Brian Orelli, PhDMomenta Moves MeticulouslyInvestors continue to wait for the outcome of the biotech's strategic review.
Aug 13, 2018 by Brian Orelli, PhDIonis Pharmaceuticals' Royalties Rise, but So Do ExpensesIt's hard to make a profit that way, but the situation seems temporary as the biotech waits for FDA approval of two drugs.
Aug 10, 2018 by Brian Orelli, PhDHere's Why CareDx Jumped 13.5% TodayA beat and a raise, what's not to like?
